Bristol told analysts during April 25 conference call that it has scheduled an R&D update for Nov. 7. The company will be through two key events before that date: the disclosure of study results for the antihypertensive Vanlev and the probable onset of generic competition for its largest product, Glucophage (1see related story, p. 16)
You may also be interested in...
A money-back guarantee will be part of Bristol-Myers Squibb's repositioning efforts for the metformin line extensions Glucophage XR and Glucovance.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials